Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
05.03.2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
05.03.2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
Guo T, Jochum W, Jörger M, Gillessen Sommer S, Blum L, Collins B, Rosenberger G, Röst H, Wolski W, Gillet L, Koh C, Kouvonen P, Aebersold R. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 2015; 21:407-13.
02.03.2015Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
02.03.2015Nat Med 2015; 21:407-13
Guo Tiannan, Jochum Wolfram, Jörger Markus, Gillessen Sommer Silke, Blum Lorenz C, Collins Ben C, Rosenberger George, Röst Hannes L, Wolski Witold E, Gillet Ludovic C, Koh Ching Chiek, Kouvonen Petri, Aebersold Ruedi
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Erber R, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Liedtke C, Moustafa Z, Gluz O, Brünner N, Kreipe H, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 2015; 150:279-88.
28.02.2015Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
28.02.2015Breast Cancer Res Treat 2015; 150:279-88
Erber Ramona, Möbus Volker, Augustin Doris, Thomssen Christoph, Jänicke Fritz, Kiechle Marion, Kuhn Walther, Nitz Ulrike, Harbeck Nadia, Liedtke Cornelia, Moustafa Zehra, Gluz Oleg, Brünner Nils, Kreipe Hans Heinrich, Pelz Enrico, Kates Ronald, Bartels Annette, Huober Jens, Mohrmann Svjetlana, Hartmann Arndt
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.
27.02.2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
27.02.2015Ann Oncol 2015; 26:873-9
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S
Influence of censoring on conclusions of trials for women with metastatic breast cancer
Templeton A, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond G, Tannock I. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer 2015
26.02.2015Influence of censoring on conclusions of trials for women with metastatic breast cancer
26.02.2015Eur J Cancer 2015
Templeton Arnoud, Ace Olga, Amir Eitan, Vera-Badillo Francisco, Ocana Alberto, Pond Gregory R, Tannock Ian F
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015; 84:1242-8.
25.02.2015Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
25.02.2015Neurology 2015; 84:1242-8
Korfel Agnieszka, Junghanß Christian, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Roth Patrick, Bamberg Michael, Pietsch Torsten, Mergenthaler Hans G, Hundsberger Thomas, Thiel Eckhard, Martus Peter, Möhle Robert, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, Fischer Thomas, Weller Michael
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
21.02.2015Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
21.02.2015Swiss Med Wkly 2015; 145:w14100
Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C. Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Invest New Drugs 2015; 33:472-9.
20.02.2015Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
20.02.2015Invest New Drugs 2015; 33:472-9
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Barbieri P, Pace S, Sessa C
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
13.02.2015Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
13.02.2015Cancer Chemother Pharmacol 2015; 75:763-72
Jörger Markus, Beijnen J H, Cerny Thomas, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P H M, Doodeman V D, Cats A, Boot H, Huitema A D R, Schellens J H M
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Fontanella C, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Huober J, Hilfrich J, Hanusch C, Lederer B, Gade S, Vanoppen M, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Loibl S. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015; 150:127-39.
13.02.2015Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
13.02.2015Breast Cancer Res Treat 2015; 150:127-39
Fontanella Caterina, Schneeweiss Andreas, Paepke Stefan, Jackisch Christian, Mehta Keyur, Nekljudova Valentina, Untch Michael, Neven Patrick, von Minckwitz Gunter, Huober Jens, Hilfrich Jörn, Hanusch Claus, Lederer Bianca, Gade Stephan, Vanoppen Mieke, Blohmer Jens Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Loibl Sibylle
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
Omlin A, Sartor O, Rothermundt C, Cathomas R, de Bono J, Shen L, Su Z, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer 2015
30.01.2015Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
30.01.2015Clin Genitourin Cancer 2015
Omlin Aurelius, Sartor Oliver, Rothermundt Christian, Cathomas Richard, de Bono Johann S, Shen Liji, Su Zhen, Gillessen Sommer Silke
Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)
Putora P, ess s, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis 2015; 32:143-9.
28.01.2015Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)
28.01.2015Clin Exp Metastasis 2015; 32:143-9
Putora Paul Martin, ess silvia, Panje Cédric, Hundsberger Thomas, van Leyen Karin, Plasswilm Ludwig, Früh Martin
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
Koeberle D, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26:709-14.
20.01.2015Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
20.01.2015Ann Oncol 2015; 26:709-14
Koeberle D, Kollar A, Saletti P, Roth A, Früh Martin, Kueng M, Popescu R A, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R
Dying: a Transition
Renz M. Dying: a Transition. New York: Columbia University Press, 2015. ISBN 9-780231-17088-8.
01.01.2015Dying: a Transition
01.01.2015Columbia University Press, ISBN 9-780231-17088-8
Renz Monika
Behandlungsoptionen von Hirnmetastasen
Hundsberger T, Hottinger A. Behandlungsoptionen von Hirnmetastasen - Neue Optionen durch orale und molekulare Therapeutika. info@onkologie 2015; 5:5-7.
01.01.2015Behandlungsoptionen von Hirnmetastasen
01.01.2015info@onkologie 2015; 5:5-7
Hundsberger Thomas, Hottinger A F
Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical Decline
Hundsberger T, Rösler K, Findling O. Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical Decline. J Neuromuscul Dis 2015; 2:S20.
01.01.2015Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical Decline
01.01.2015J Neuromuscul Dis 2015; 2:S20
Hundsberger Thomas, Rösler Kai M, Findling Oliver
Das Adenoidzystische-Karzinom
AC V, Siano M, Broglie Däppen M, Toepfer M, Stöckli S. Das Adenoidzystische-Karzinom. info@onkologie.ch 2015; 1:10-12.
01.01.2015Das Adenoidzystische-Karzinom
01.01.2015info@onkologie.ch 2015; 1:10-12
AC Volck, Siano Marco, Broglie Däppen Martina, Toepfer Michael, Stöckli Sandro
Antiemese und Tumormedikation
Zürrer-Härdi U, Siano M, Blum D. Antiemese und Tumormedikation. info@onkologie.ch 2015; 1:20-26.
01.01.2015Antiemese und Tumormedikation
01.01.2015info@onkologie.ch 2015; 1:20-26
Zürrer-Härdi Ursina, Siano Marco, Blum David
Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag
Siano M. Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag. Leading Opinions Hämatologie / Onkologie 2015; 4
01.01.2015Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag
01.01.2015Leading Opinions Hämatologie / Onkologie 2015; 4
Siano Marco
Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia
Litschel R, Siano M, Tasman A, Cogliatti S. Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia. Allergy Rhinol (Providence) 2015; 6:191-4.
01.01.2015Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia
01.01.2015Allergy Rhinol (Providence) 2015; 6:191-4
Litschel Ralph, Siano Marco, Tasman Abel-Jan, Cogliatti Sergio B.